{
    "clinical_study": {
        "@rank": "159826", 
        "arm_group": [
            {
                "arm_group_label": "Bisoprolol sub-group A", 
                "arm_group_type": "Experimental", 
                "description": "Subjects who received monotherapy of bisoprolol 5 milligram (mg) before trial inclusion will be randomized to bisoprolol sub-group A."
            }, 
            {
                "arm_group_label": "Bisorprolol sub-group B", 
                "arm_group_type": "Experimental", 
                "description": "Subjects who received monotherapy of bisoprolol 5 mg before trial inclusion will be randomized to bisoprolol sub-group B."
            }, 
            {
                "arm_group_label": "Amlodipine sub-group A", 
                "arm_group_type": "Experimental", 
                "description": "Subjects who received monotherapy of amlodipine 5 mg before trial inclusion will be randomized to bisoprolol sub-group A."
            }, 
            {
                "arm_group_label": "Amlodipine sub-group B", 
                "arm_group_type": "Experimental", 
                "description": "Subjects who received monotherapy of amlodipine 5 mg before trial inclusion will be randomized to bisoprolol sub-group B."
            }
        ], 
        "brief_summary": {
            "textblock": "This is a randomized, comparative  Phase 3 trial to investigate the efficacy of fixed dose\n      combination (FDC) of bisoprolol and amlodipine in hypertensive subjects."
        }, 
        "brief_title": "Fixed Dose Combination of Bisoprolol and Amlodipine in the Treatment of Hypertension", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Hypertension", 
        "condition_browse": {
            "mesh_term": "Hypertension"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Essential hypertension not controlled at 5 mg bisoprolol or 5 mg amlodipine at least\n             4 weeks (definition of not controlled: SBP greater than or equal to (>=) 140\n             millimeter of mercury (mmHg) with or without DBP >= 90 mmHg)\n\n          -  Male or female subjects >=18 years of age, without limitation on race\n\n          -  Medically accepted effective contraception if procreative potential exists\n             (applicable for both male and female subjects until at least 90 days after the last\n             dose of trial treatment)\n\n          -  Subjects who have signed the informed consent form before any trial related\n             assessment\n\n        Exclusion Criteria:\n\n          -  General contraindications of beta-blockers and/or calcium channel blockers\n\n               -  Previous and concurrent acute heart failure or during episodes of heart failure\n                  decompensation requiring intravenous inotropic therapy\n\n               -  Concurrent cardiogenic shock\n\n               -  Previous and concurrent second or third degree atrioventricular (AV) block\n                  (without a pacemaker)\n\n               -  Previous and concurrent sick sinus syndrome\n\n               -  Previous and concurrent sinoatrial block\n\n               -  Concurrent symptomatic bradycardia\n\n               -  Concurrent symptomatic hypotension\n\n               -  Previous and concurrent severe bronchial asthma or chronic obstructive pulmonary\n                  diseases\n\n               -  Previous and concurrent severe peripheral arterial occlusive diseases and\n                  Raynaud's syndrome\n\n               -  Untreated pheochromocytoma\n\n               -  Concurrent metabolic acidosis\n\n               -  Known hypersensitivity to bisoprolol, amlodipine, dihydropyridine derivates or\n                  to any of the excipients\n\n          -  Seated pulse rate less than 60 beats per minute (bpm) at screening\n\n          -  Any other anti-hypertensive drugs (other than bisoprolol and amlodipine) are used\n             within 4 weeks prior to the screening visit\n\n          -  Use of any enzyme-modifying drugs acting on cytochrome P450 (CYP) 3A4 enzymes via\n             inhibition (such as ketoconazole, itraconazole, ritonavir) or induction (such as\n             rifampicin or hypericum perforatum) within 28 days before Day 1 of the trial\n\n          -  Other significant disease that in the Investigator's opinion that would exclude the\n             subject from the trial, such as uncontrolled diabetes mellitus, severe liver and/or\n             kidney dysfunction, decompensated cardiac failure\n\n          -  Any other condition or therapy which in the Investigator's opinion would pose a risk\n             to the subject or interfere with the trial objectives\n\n          -  Concurrent alcohol and/or drug abuse\n\n          -  Known hypersensitivity to the trial treatments\n\n          -  Pregnancy and lactation period. All female subjects with reproductive potential must\n             have a negative pregnancy serum test within the 7 days prior to enrollment\n\n          -  Known lack of subject compliance\n\n          -  Legal incapacity or limited legal capacity\n\n          -  Participation in another clinical trial within the previous 30 days\n\n          -  Persons directly involved in the execution of the protocol"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 31, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01977794", 
            "org_study_id": "200006-524"
        }, 
        "intervention": [
            {
                "arm_group_label": "Bisoprolol sub-group A", 
                "description": "Bisoprolol/Amlodipine fixed dose combination (FDC) tablet will be orally administered as an initial dose of 5 milligram (mg)/5 mg once daily for 6 weeks. If blood pressure is controlled at Day 43 (Visit 2), the same dose will continue for next 6 weeks.  If the blood pressure is uncontrolled at Visit 2, the dose will be increased to Bisoprolol/Amlodipine 5mg/10mg for following 6 weeks. Subjects who received Bisoprolol/Amlodipine 5mg/10mg after Visit 2 and are controlled at visit 3, will continue with the same dose for next 6 weeks. If the blood pressure is uncontrolled, subjects dose will be increased to Bisoprolol/Amlodipine 10mg/10mg until Day 127.", 
                "intervention_name": "Bisoprolol/Amlodipine (Bisoprolol sub-group A)", 
                "intervention_type": "Drug", 
                "other_name": "Concor AM"
            }, 
            {
                "arm_group_label": "Bisorprolol sub-group B", 
                "description": "Bisoprolol/Amlodipine FDC tablet will be orally administered as an initial dose of 5 mg/5 mg once daily for 6 weeks. If blood pressure is controlled at Day 43 (Visit 2), the same dose will continue for next 6 weeks.  If the blood pressure is uncontrolled at Visit 2, the dose will be increased to Bisoprolol/Amlodipine 10mg/5mg for following 6 weeks. Subjects who received Bisoprolol/Amlodipine 10mg/5mg after Visit 2 and are controlled at visit 3, will continue with the same dose for next 6 weeks. If the blood pressure is uncontrolled, subjects dose will be increased to Bisoprolol/Amlodipine 10mg/10mg until Day 127.", 
                "intervention_name": "Bisoprolol/Amlodipine (Bisoprolol sub-group B)", 
                "intervention_type": "Drug", 
                "other_name": "Concor AM"
            }, 
            {
                "arm_group_label": "Amlodipine sub-group A", 
                "description": "Bisoprolol/Amlodipine FDC tablet will be orally administered as an initial dose of 5 mg/5 mg once daily for 6 weeks. If blood pressure is controlled at Day 43 (Visit 2), the same dose will continue for next 6 weeks. If the blood pressure is uncontrolled at Visit 2, the dose will be increased to Bisoprolol/Amlodipine 5mg/10mg for following 6 weeks. Subjects who received Bisoprolol/Amlodipine 5mg/10mg and are controlled at Visit 3, will continue with the same dose for next 6 weeks. If the blood pressure is uncontrolled, subjects dose will be increased to Bisoprolol/Amlodipine 10mg/10mg until Day 127.", 
                "intervention_name": "Bisoprolol/Amlodipine (Amlodipine sub-group A)", 
                "intervention_type": "Drug", 
                "other_name": "Concor AM"
            }, 
            {
                "arm_group_label": "Amlodipine sub-group B", 
                "description": "Bisoprolol/Amlodipine FDC tablet will be orally administered as an initial dose of 5 mg/5 mg once daily for 6 weeks. If blood pressure is controlled at Day 43(Visit 2), the same dose will continue for next 6 weeks. If the blood pressure is uncontrolled at Visit 2, the dose will be increased to Bisoprolol/Amlodipine 10mg/5mg for following 6 weeks. Subjects who received Bisoprolol/Amlodipine 10mg/5mg and are controlled at Visit 3, will continue with the same dose for next 6 weeks. If the blood pressure is uncontrolled, subjects dose will be increased to Bisoprolol/Amlodipine 10mg/10mg until Day 127.", 
                "intervention_name": "Bisoprolol/Amlodipine (Amlodipine sub-group B)", 
                "intervention_type": "Drug", 
                "other_name": "Concor AM"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Amlodipine", 
                "Bisoprolol"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Bisoprolol", 
            "Amlodipine", 
            "Fixed dose combination (FDC)", 
            "Systolic Blood Pressure (SBP)", 
            "Diastolic Blood Pressure (DBP)"
        ], 
        "lastchanged_date": "October 31, 2013", 
        "location": {
            "contact": {
                "email": "service@merckgroup.com", 
                "phone": "+49 6151 72 5200"
            }, 
            "facility": {
                "address": {
                    "city": "Darmstadt", 
                    "country": "Germany"
                }, 
                "name": "Please contact the Merck KGaA Communication Center located in"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Randomized, Comparative Trial of Concor AM, a Fixed Dose Combination of Bisoprolol and Amlodipine, on the Treatment of Essential Hypertensive Patients Whose Blood Pressure is Not Well Controlled by Monotherapy of Bisoprolol 5mg or Amlodipine 5mg", 
        "overall_contact": {
            "email": "service@merckgroup.com", 
            "last_name": "Merck KGaA Communication Center", 
            "phone": "+49 6151 72 5200"
        }, 
        "overall_official": {
            "affiliation": "Merck S.A., Brazil, an affiliate of Merck KGaA, Darmstadt, Germany", 
            "last_name": "Regional medical director LATAM", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "Brazil: National Committee of Ethics in Research", 
                "Brazil: National Health Surveillance Agency", 
                "Guatemala: Ministry of Public Health and Social Assistance"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Mean reduction of  systolic blood pressure (SBP) after 18 weeks of treatment from Baseline (latest SBP before study treatment)", 
            "safety_issue": "No", 
            "time_frame": "Baseline and Week 18"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01977794"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from Baseline (latest diastolic blood pressure [DBP] before study treatment) in DBP after 18 weeks of treatment", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 18"
            }, 
            {
                "measure": "Percentage of subjects with controlled blood pressure under different dosages of after study treatment", 
                "safety_issue": "No", 
                "time_frame": "Baseline up to Day 127 (end of trial)"
            }, 
            {
                "measure": "Change from Baseline (latest heart rate [HR] before study treatment) in HR after 18 weeks treatment", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 18"
            }, 
            {
                "measure": "Number of subjects with adverse events (AEs)", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline up to Day 127 (end of trial)"
            }
        ], 
        "source": "Merck KGaA", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck KGaA", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}